S01654 Summary:

BILL NOS01654
 
SAME ASNo Same As
 
SPONSORORTT
 
COSPNSROBERACKER
 
MLTSPNSR
 
Amd §2500-a, add §2500-m, Pub Health L
 
Requires the testing of newborns for spinal muscular atrophy; requires the department of health to educate the public and distribute informational materials on spinal muscular atrophy.
Go to top    

S01654 Actions:

BILL NOS01654
 
01/13/2023REFERRED TO HEALTH
01/03/2024REFERRED TO HEALTH
Go to top

S01654 Committee Votes:

Go to top

S01654 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

S01654 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          1654
 
                               2023-2024 Regular Sessions
 
                    IN SENATE
 
                                    January 13, 2023
                                       ___________
 
        Introduced  by  Sen.  ORTT  --  read twice and ordered printed, and when
          printed to be committed to the Committee on Health
 
        AN ACT to amend the public health law, in relation  to  the  testing  of
          newborns for spinal muscular atrophy and public education thereon
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Subdivision 1 of section 2500-a of the public  health  law,
     2  as  amended by chapter 730 of the laws of 2021, paragraph (j) as amended
     3  by chapter 70 of the laws of 2022, is amended to read as follows:
     4    1. It shall be the duty of the administrative officer or other  person
     5  in  charge  of  each institution caring for infants twenty-eight days or
     6  less of age and the person required in pursuance of  the  provisions  of
     7  section  forty-one  hundred thirty of this chapter to register the birth
     8  of a child, to cause to have administered to every such infant or  child
     9  in  its or his care a test for diseases and conditions designated by the
    10  commissioner under regulations of the commissioner, and for:
    11    (a) Phenylketonuria[.];
    12    (b) Homozygous sickle cell disease[.];
    13    (c) Hypothyroidism[.];
    14    (d) Branched-chain ketonuria[.];
    15    (e) Galactosemia[.];
    16    (f) Homocystinuria[.];
    17    (g) Critical congenital heart defects through pulse  oximetry  screen-
    18  ing[.];
    19    (h)  With  regard  to  any  newborn  infant  who  is identified as, or
    20  suspected of, having a hearing impairment as a  result  of  a  screening
    21  conducted  pursuant  to  section  twenty-five hundred-g of this title, a
    22  urine polymerase chain reaction (PCR) test for  cytomegalovirus,  unless
    23  the  parent  of the infant objects thereto; provided that if the commis-
    24  sioner determines that another  test  for  cytomegalovirus  is  diagnos-
    25  tically equivalent to or better than the urine polymerase chain reaction

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD05581-01-3

        S. 1654                             2
 
     1  test,  the  commissioner may, by regulation under this section, allow or
     2  require the use of that other test[.];
     3    (i) Adrenoleukodystrophy[.];
     4    (j)  Glucose-6-phosphate dehydrogenase deficiency using a quantitative
     5  enzymatic test or other diagnostic test  in  cases  where:  the  newborn
     6  infant  presents with hemolytic anemia, hemolytic jaundice, or early-on-
     7  set increasing neonatal jaundice, that  is,  jaundice  (bilirubin  level
     8  greater than fortieth percentile for age in hours) persisting beyond the
     9  day  of  birth through the week after birth; the newborn infant has been
    10  admitted to the hospital for jaundice following birth; or the biological
    11  parent of the newborn infant indicates a family, racial, or ethnic  risk
    12  of   glucose-6-phosphate   dehydrogenase  deficiency,  including  having
    13  significant African, Asian, Mediterranean, or Middle  Eastern  ancestry;
    14  and
    15    (k) spinal muscular atrophy.
    16    §  2.  The public health law is amended by adding a new section 2500-m
    17  to read as follows:
    18    § 2500-m. Spinal muscular atrophy public education. 1. The  department
    19  shall  develop  and  publish  informational  materials for women who may
    20  become pregnant, expectant parents and parents of infants regarding:
    21    (a) the incidence of spinal muscular atrophy;
    22    (b) the risks of spinal muscular atrophy;
    23    (c) birth defects caused by spinal muscular atrophy;
    24    (d) methods of diagnosing spinal muscular atrophy; and
    25    (e)  available  methods  of  treating  spinal  muscular  atrophy   and
    26  resources  available  for families of children born with spinal muscular
    27  atrophy.
    28    2. The department shall publish the information required  pursuant  to
    29  subdivision  one of this section on its internet website, and distribute
    30  information regarding birth defects,  treatment  and  resources  to  all
    31  hospitals performing spinal muscular atrophy testing pursuant to section
    32  twenty-five hundred-a of this title.
    33    3.  The  department  may promulgate rules to implement the purposes of
    34  this section.
    35    § 3. This act shall take effect immediately; except that  section  one
    36  of  this act shall take effect on the one hundred twentieth day after it
    37  shall have become a law. Effective immediately, the addition,  amendment
    38  and/or repeal of any rule or regulation necessary for the implementation
    39  of  section  one  of this act on its effective date are authorized to be
    40  made and completed on or before such effective date.
Go to top